Abstract: The invention relates to a method of use, of a mixture of chemical compounds for a shark repellent, as well as methods of protection garments in using such material(s). Generally, there are not many shark repellents. This shark repellent contains a mixture of chemical compounds that are highly toxic and trenchant, which will deter the shark from injured or non-injured humans or animals, once the mixture is immersed in water.

Abstract: The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof.

Abstract: There is proposed a method for using a preparation for lowering the cholesterol level of a patient. In preferred embodiments, the preparation essentially consists of an active substance being an aqueous solution of formaldehyde with a concentration of 36.5-40%, the active substance constitutes 2-6 weight units, and an additive being an isotonic solution of sodium chloride with a concentration of 0.85-0.95%, the additive constitutes from 998 to 994 weight units accordingly, to make the total of 1000 weight units. The method includes administering the preparation to the patient in the form of intramuscular injections with a predetermined dose at a predetermined time interval, thereby lowering the cholesterol level of the patient. It is preferable to choose the predetermined time interval from the group consisting of 7, 21, 30, and 60 days. It is also preferable to choose the predetermined dose in the amount of 5 mL.

Abstract: The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.

Abstract: There is proposed a method for using a preparation for lowering the cholesterol level of a patient. In preferred embodiments, the preparation essentially consists of an active substance being an aqueous solution of formaldehyde with a concentration of 36.5-40%, the active substance constitutes 2-6 weight units, and an additive being an isotonic solution of sodium chloride with a concentration of 0.85-0.95%, the additive constitutes from 998 to 994 weight units accordingly, to make the total of 1000 weight units. The method includes administering the preparation to the patient in the form of intramuscular injections with a predetermined dose at a predetermined time interval, thereby lowering the cholesterol level of the patient. It is preferable to choose the predetermined time interval from the group consisting of 7, 21, 30, and 60 days. It is also preferable to choose the predetermined dose in the amount of 5 mL.

Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.

Abstract: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.

Abstract: The invention relates to medicine, in particular to medicinal preparations directed at activating own stem cells of a human body. The aim of the invention is to develop a non-toxic agent which does not produce side effects and is used for activating the stem cells of an organism. The proposed method for producing the agent involves taking a 37-40% medicinal formaldehyde solution and adding it into a 0.9-0.95% sterile sodium chloride solution used for injections in such a way that a 0.00003-0.003% formaldehyde solution is obtained. The agent should be stored in a dark place at a temperature of 15-35° C.

Abstract: The invention relates to medicine and can be used for producing a medicinal agent for normalising the cholesterol level. The aim of the invention is to develop a physiologically acceptable cholesterol-control agent which is nontoxic and does not cause addiction of organism. In preferred embodiments, the method for producing said agent consists in using 2-6 weight parts of a 36.5-40.0% formaldehyde medicinal solution and in adding 998-994 weight parts of a sterile 0.85-0.95% sodium chloride solution which is used for injection in such a way as to produce a 0.07-024% formaldehyde solution. The agent is stored at a temperature of 15-35° C. It also encompasses a method for treatment of patients for lowering their cholesterol levels that comprises administering the agent to the patients as intramuscular injections with a predetermined dose at a predetermined time interval.

Abstract: Aqueous formaldehyde solutions are prepared and the formaldehyde content of the aqueous formaldehyde solutions produced is determined by an online analytical method. The desired formaldehyde content can subsequently be established by addition of water so that an aqueous formaldehyde solution having a defined formaldehyde content (formalin) is obtained.

Abstract: The present invention provides methods for treating tissue to inhibit post-implant calcification of a biological tissue. In one method of this invention, a tissue is immersed in or otherwise contacted with a pretreated glutaraldehyde solution, i.e., a heat-treated or pH-adjusted glutaraldehyde solution. The tissue may be partially fixed with glutaraldehyde prior to, after, or concurrently with the step of contacting the tissue with the pretreated gluteraldehyde. Contact with the pretreated gluteraldehyde produces free amine groups on the tissue, which are subsequently blocked by contacting the crosslinked tissue with a blocking agent. In another embodiment, a tissue is contacted with either a non-pretreated glutaraldehyde or a pH-adjusted glutaraldehyde solution for a period of time sufficient to crosslink the tissue. The crosslinked tissue is then treated with a reducing agent that reduces aldehyde and carboxylic acid groups on the fixed tissue.

Abstract: A cytostatic composition comprising an effective amount of an aldehyde in a pharmacological salt solution is shown to be effective at inhibiting growth of a number of cancerous cell lines.

Abstract: A novel, new, and highly effective agent for promoting fat degradation that contains astaxanthin and/or an ester thereof as active ingredient is provided. The agent for promoting fat degradation of the present invention has an effect of reducing fat by lipolysis of fat in either a subject who is in a condition in which fat has already accumulated or a subject who is in a condition in which fat has not yet been accumulated. Accordingly, the agent for promoting fat degradation of the present invention can restore hypertrophied adipocytes to a normal size.

Abstract: This invention relates to compositions for disinfecting an inanimate surface comprising an effective disinfecting amount of a disinfectant and water, which water comprises from about 99.760 to about 99.999% of light isotopologue 1H2 160 and up to 100% of residual isotopologues 1H2170, 1H2180, 1H2H160, 1H2H170, 1H2H180, 2H2160, 2H2170, and 2H2180. The disinfectant is selected from the group consisting of aldehydes, alcohols, phenol compounds, quaternary ammonium compounds, chlorhexidine, halogen compounds, peroxides and hydroperoxides. Further, the invention relates to method of disinfecting an inanimate surface, which comprises a step of contacting said surface with the composition of the present invention.

Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.

Abstract: Nanobacteria contribute to pathological calcification in the human and animal body, including diseases such as kidney stones, salivary gland stones, dental pulp stones and atherosclerosis. The present invention provides methods for sterilizing articles contaminated with nanobacteria. The present invention also provides methods of treating patients infected with nanobacteria. In particular, the present invention provides a method for preventing the recurrence of kidney stones in a patient that has suffered from kidney stones, comprising administration of an antibiotic, a bisphosphonate, or a calcium chelator, either alone or in combination, in an amount effective to inhibit or prevent the growth and development of nanobacteria.

Abstract: The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

Abstract: The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.

Abstract: A process for permeabilizing erythrocytes in which the erythrocytes are subjected successively to the action of (a) a fixing agent containing an aliphatic aldehyde and oligosaccharide, (b) a permeabilizing agent containing a detergent and an oligosaccharide, kit for permeabilizing erythrocytes, kit for immuno-marking fetal erythrocytes, and a process for identifying fetal erythrocytes by immuno-marking.

Abstract: This invention provides methods of inactivating a microorganism and preparing a vaccine including the step of applying to said microorganism a cross-linking agent simultaneously with a separate inactivant. This invention further relates to vaccine prepared by such methods and a kit including such inactivated microorganism. The cross-linking agent is typically formaldehyde (FA) and the inactivant typically binary ethyleneimine (BEI).

Abstract: The invention relates e.g. to the use of aldehydes and/or ketones for improving the stability of cosmetic formulations containing butylmethoxydibenzoylmethane as organic light protection filters in conjunction with inorganic light protection filters.

Abstract: An anthelmintic composition including an Antibiotic S541 compound or a chemical derivative thereof, together with an insoluble anthelmintic compound. The composition is stabilized by between about 0.15% and about 5.0% of an antioxidant by weight of the total composition.

Abstract: Disclosed herein are novel cautery devices, and methods and kits implementing the same. The disclosed devices are especially useful for localized delivery of a liquid caustic agent to treat various defects associated with malformations and injuries resulting in chronic or acute bleeding, or to ablate tumors, occlude fistulae or other luminal structures. The disclosed devices have uses in a number of medical disciplines, and specific examples are provided pertaining to treatment of defects, malformations, and injuries, or bleeding due to medical procedures, in and along the gastrointestinal tract.

Abstract: The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

Abstract: A method and composition for quenching formaldehyde fixation of cell and tissue specimens. The composition includes a formaldehyde-reactive agent. The formaldehyde-reactive agent reacts with the formaldehyde to quench the fixation of the cell or tissue specimen. The method involves contacting a formaldehyde fixative solution with the composition.

Abstract: Disclosed are biocidal compositions comprising mixtures of formaldehyde-releasing imidazolidines, such as 1,3-dimethylol-5,3-dimethylhydantoin, and 3-isothiazolones stabilized with low levels of copper salts.

Abstract: Disclosed is a method of inhibiting the growth of microorganisms in, at, or on a locus subject to microbial attack, comprising introducing to said locus an antimicrobially effective amount of at least one dihaloformaldoxime carbamate.

Abstract: A composition and method for preventing and/or reducing stench and septicity from animal waste comprising a sulfur and oxygen-bearing component and one or more aldehydes and/or one or more ketones. The sulfur and oxygen-bearing component is selected from the group consisting of sodium bisulfite, potassium bisulfite, lithium bisulfite, sodium metabisulfite, potassium metabisulfite, lithium metabisulfite, sodium hydrosulfite, potassium hydrosulfite, lithium hydrosulfite and hydrogen sulfite. The aldehyde is selected from the group consisting of formaldehyde, glyoxal, glutaraldehyde, benzaldehyde, acetaldehyde, butryaldehyde, cinnamaldehyde, anisaldehyde, salicylaldehyde, citral, glycolic aldehyde, paraldehyde, metaldehyde, heptylaldehyde, octylaldehyde and decylaldehyde. The ketone is selected from the group consisting of diacetyl, ionone, pseudo-ionone, acetylacetone, 3-buten-2-one, mesityl oxide, acetone, methyl ethyl ketone, diethyl ketone and dipropyl ketone.

Abstract: Delivery of fuel and cofactors augments ATP production in cells, and mitigates damages in ischemic or metabolically impaired tissues. The processes may be particularly effective in acute or chronic ischemic conditions, for reversing anesthesia, for treating diabetes, for producing or preventing coma due to lack of fuel or ATP, for reversing processes of aging, as dietary supplements, as performance enhancers, for example, in sports, for tissue transplantation and other surgery, and for cold storage or cryopreservation of tissues such as organs.

Abstract: Compounds of the formula ##STR1## wherein the substituents are as defined herein, are disclosed. Pharmaceutical compositions and methods of treating allergic and inflammatory diseases are also taught.

Abstract: A preparation for lysing erythrocytes, characterized herein so far as the aqueous preparation with a substantially physiological ionic strength comprising a mixture:of an aliphatic aldehyde,of a polyhydric alcohol and,of a salt of a strong acid and of an alkali metal or an alkaline earth metal.

Abstract: Methods and kits for reducing the transmission of infectious agents contained in biological fluid samples are provided. The methods include contacting the biological sample with a fixative solution containing a fixative present at a concentration sufficient to simultaneously disinfect the sample and fix analytes contained therein.

Abstract: Aqueous disinfectant concentrate which includes succinic dialdehyde, glutaraldehyde and/or formaldehyde, one or more alcohols of limited water miscibility and optionally usual auxiliaries. By diluting with water, a working solution can be prepared from the concentrate. The advantages of the new disinfectant concentrate or disinfectant are the reduced development of odor, an improved material compatibility, an improved microbicidal effectiveness and a clearly increased storage-stability. Furthermore, the activation usual up until now with disinfectants based on aldehyde is superfluous. Preferred application fields are surface and instrument disinfection.

Abstract: Alkene aldehyde sulfoxylates are more effective than their saturated aldehyde sulfoxylate counterparts as systemic pesticides for protecting plants.

Abstract: Phosphonium salts such as THP and aldehydes such as formaldehyde exhibit synergistic biocidal activity.

Abstract: Polymer-based composition effective for disinfecting and for sterilizing plus cleaning and/or lubricating devices. The composition contains, in solution, a hydrophilic polymer serving as a water-based lubricant, a disinfectant, and a surfactant. The addition of a hydrophilic polymer forms an anti-corrosive formula for sterilizing, disinfecting, cleaning, and lubricating devices including medical and dental devices where the efficacy of cleaning and sterilizing is enhanced by the addition of a hydrophilic polymer.

Abstract: Disinfectant mixture containing water soluble lubricating and cleaning agents comprising a water-based polymer serving as a water-based lubricant, a disinfectant and deionized water.

Abstract: An alkali-metal dithionite is readily transformed into an aldehyde sulfoxylate microbicide which is absorbed through plant leaves and is more stable against oxidation.

Abstract: Method of preparing a fixed biological implantation material in which an implantation material is fixed with an aldehyde and the excess aldehyde is bound by an aminodicarboxylic acid in an acidic medium.

Abstract: A method to inactivate viruses or to disinfect blood products, for instance units of red blood cells, wherein a disinfectant or virus inactivating chemical is made isotonic or nearly isotonic, and wherein the red blood cells are exposed to isotonic disinfectant to inactivate any agent which may be present, for example HIV-1 virus which causes AIDS. The method may also be applied to plasma fractions and corneas.

Abstract: Very potent, stable, ordorless, and phenol-free virciudal solutions are active at high dilution when used for surface decontamination of animate and inanimate objects. The virucidal compositions described are efficacious in a matter of minutes against both the lipophilic and the more resistant hydrophilic viruses. The three active ingredients in these virucidal compositions are the glutaraldehyde monomer in equilibrium with its hydrates and polymers, hydrogen-bonded glycol molecules to eliminate aldehydes odor, and an anionic surfactant of the alkyl sulfate, alkyl sulfonate, alcohol sulfate or alkyl aryl sulfonate type. A preferred anionic surfactant would be the Sodium Dodecyl Sulfate (SDS), which exhibits strong cidal synergism against the Herpes Simplex Virus type 1 when mixed at a concentration as low as 0.0005% in diluted glutaraldehyde aqueous solutions (0.0025%). Improved virucidal killing at higher dilutions of the same formula were observed with the more resistant Coxsackie B viruses.

Abstract: A technique and receptacle for disinfecting biological fluids such as whole blood is described in which the disinfectant is prepositioned in a receptacle for biological fluids utilized for clinical evaluation in an amount which is sufficient to disinfect the fluid without interfering with subsequent clinical evaluation. The invention is specifically directed to disinfecting viral contaminants in blood by providing a closed container for the blood specimen which contains an amount of a disinfectant sufficient to destroy without otherwise affecting the integrity of the specimen for future evaluation. The amount of disinfectant positioned in the container is adjusted to provide an ultimate concentration in the blood specimen of aldehyde of about 0.001 to 5.0 weight percent and is buffered to a pH of about 7.2 to 8.5 percent preferably about 7.4.

Abstract: Composition for use as a pulpotomy agent having glutaraldehyde as the active ingredient in a solution stabilized by a buffer suitable for maintaining the pH of the glutaraldehyde solution at near-physiological levels. The stable composition also includes the anti-oxidants sodium nitrite and glycerol. The composition is used by direct application to infected coronal pulp tissue to fix the tissues and prevent further deterioration caused by pulpitis. A method of treating the infected tissue prior to dental restoration is also disclosed.

Abstract: HTLV-III virus in blood or blood components is inactivated by treatment with about 0.1-5% of phenol, formaldehyde, or mixtures thereof, at a temperature of about 2.degree.-40.degree. C. for at least about 5 minutes.

Abstract: In the cleaning and disinfection of endoscopes, the endoscope surfaces to be cleaned are successively(a) brought into contact with a cleaning solution which is heated to 55.degree. to 65.degree. C., kept at that temperature for 1 to 15 minutes and then drained off and which contains a low-foam nonionic surfactant, a proteolytic enzyme, at least one complexing agent and, optionally, other standard detergent constituents, and has a pH value of from 6 to 8;(b) brought into contact with a disinfectant solution which is heated to 55.degree. to 65.degree. C., kept at that temperature for 1 to 15 minutes and then separated off and which contains an aldehyde selected from the group consisting of formaldehyde and aliphatic C.sub.2 -C.sub.8 dialdehydes and at least one complexing agent, and has a pH value of from 6 to 8;(c) washed at least twice with water of which the pH value is adjusted to pH 6-8, the water being heated to 55.degree. to 65.degree. C.

Abstract: The present invention provides silicone-water emulsions formed from volatile cyclic polysiloxanes which are emulsified with a preblended mixture of water and a combination of emulsifying agents. Highly ethoxylated nonionic emulsifying agents are particularly well-suited for the formation of stable silicone-water emulsions from volatile cyclic polysiloxanes. These volatile silicone-water emulsions can be combined with epidermal enhancing agents for cosmetic and medicinal purposes.

Abstract: Embalming preparations, which are far less noxious than previously known compositions, comprise a combination of a disinfectant and a plant growth regulating compound. The compositions achieve anti-microbial potency at concentrations of these ingredients far lower than the concentration levels of disinfectants found in known embalming preparations.

Abstract: Cataract formation in mammalian lenses can be prevented or reversed by applying a solution of an aldehyde, an acrylamide or a glycol to the lens under conditions that permit the solution to interact with the lens constituents.